Prevalence of linezolid resistance in Streptococcus pneumoniae isolates: a systematic review and meta-analysis

被引：1

作者：

Heidari, Mohsen ^{[1
]}

Dashtbin, Shirin ^{[2
,3
]}

Asadi, Arezoo ^{[4
]}

Asadollahi, Parisa ^{[5
]}

Khatib, Ali ^{[6
,11
]}

Ebrahimi, Mohammad Amin ^{[7
]}

Ghanbari, Zahra ^{[7
]}

Darbandi, Atieh ^{[8
]}

Ghanavati, Roya ^{[9
]}

Pakzad, Reza ^{[10
]}

机构：

[1] Sabzevar Univ Med Sci, Cellular & Mol Res Ctr, Sabzevar, Iran

[2] Iran Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran

[3] Iran Univ Med Sci, Microbial Biotechnol Res Ctr, Tehran, Iran

[4] Iran Univ Med Sci IUMS, Inst Endocrinol & Metab, Endocrine Res Ctr, Tehran, Iran

[5] Ilam Univ Med Sci, Fac Med, Microbiol Dept, Ilam, Iran

[6] Islamic Azad Univ, Sch Med Sci, Dept Nursing, Yazd branch, Yazd, Iran

[7] Sabzevar Univ Med Sci, Student Res Comm, Sabzevar, Iran

[8] Shahed Univ, Mol Microbiol Res Ctr, Tehran, Iran

[9] Behbahan Fac Med Sci, Sch Med, Behbahan, Iran

[10] Ilam Univ Med Sci, Fac Hlth, Dept Epidemiol, Ilam, Iran

[11] Neyshabur Univ Med Sci, Fac Nursing & Midwifery, Dept Nursing, Neyshabur, Iran

来源：

FUTURE MICROBIOLOGY | 2024年 / 19卷 / 05期

关键词：

community-acquired pneumonia; linezolid; resistant; Streptococcus pneumoniae; treatment; IN-VITRO ACTIVITY; RESPIRATORY-TRACT PATHOGENS; PROTEKT SURVEILLANCE; SPECTRUM ANALYSIS; LEADER PROGRAM; UNITED-STATES; SUSCEPTIBILITY; OXAZOLIDINONE; INFECTIONS; AGENTS;

D O I：

10.2217/fmb-2023-0170

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Aim: This study aimed to understand the current level of linezolid (LNZ) resistance in Streptococcus pneumoniae isolates reported over the past 10 years. Material & methods: An electronic search was conducted for the following keywords: ((Streptococcus pneumoniae [title/abstract]) OR (Pneumococcus [title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). Result: Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among S. pneumoniae isolates ranged from 0% to 4.86%. Discussion: Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.

引用

页码：449 / 459

页数：11

共 38 条

[1] Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients [J].

Bishop, E ;

Melvani, S ;

Howden, BP ;

Charles, PGP ;

Grayson, ML .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1599-1602

[2] Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe:: report from the Zyvox® antimicrobial potency study (ZAPS-Europe) [J].

Bolmstrom, A ;

Ballow, CH ;

Qwarnstrom, A ;

Biedenbach, DJ ;

Jones, RN .

CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (12) :791-800

[3] Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections [J].

Brickner, Steven J. ;

Barbachyn, Michael R. ;

Hutchinson, Douglas K. ;

Manninen, Peter R. .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (07) :1981-1990

[4] Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections [J].

Chien, JW ;

Kucia, ML ;

Salata, RA .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :146-151

[5] Community-acquired pneumonia as an emergency condition [J].

Cilloniz, Catia ;

Dominedo, Cristina ;

Garcia-Vidal, Carolina ;

Torres, Antoni .

CURRENT OPINION IN CRITICAL CARE, 2018, 24 (06) :531-539

[6] Linezolid [J].

Clemett, D ;

Markham, A .

DRUGS, 2000, 59 (04) :815-827

[7] Antibiotic use and resistance of Streptococcus pneumoniae in The Netherlands during the period 1994-1999 [J].

de Neeling, AJ ;

Overbeek, BP ;

Horrevorts, AM ;

Ligtvoet, EEJ ;

Goettsch, WG .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (03) :441-444

[8] Oxazolidinone antibiotics [J].

Diekema, DJ ;

Jones, RN .

LANCET, 2001, 358 (9297) :1975-1982

[9] In vitro activity of linezolid against key gram-positive organisms isolated in the United States: Results of the LEADER 2004 surveillance program [J].

Draghi, DC ;

Sheehan, DJ ;

Hogan, P ;

Sahm, DF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) :5024-5032

[10] LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States [J].

Farrell, David J. ;

Mendes, Rodrigo E. ;

Ross, James E. ;

Sader, Helio S. ;

Jones, Ronald N. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (08) :3684-3690

← 1 2 3 4 →